Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
The HIV Netherlands Australia Thailand Research Collaboration |
---|---|
Information provided by: | The HIV Netherlands Australia Thailand Research Collaboration |
ClinicalTrials.gov Identifier: | NCT00476411 |
The prevalence of Hepatitis B core antigen in the Thai population is about 70 %, no data of isolated Hepatitis B core antigen is reported. Hepatitis B core antigen is observed in 10%-20% of individuals from low endemic areas of HBV infection. However, this prevalence of isolated antiHBc would be higher in endemic area of HBV infection. There is conflicting data of occult HBV infection in HIV infected patients. In Thailand, perinatal transmission is the main route of transmission which is different from developed countries. Therefore, isolated antiHBc in Thai people has longer duration than low prevalence regions. Moreover, HBV genotype C and B is common in this region. If the HBV vaccination could eliminate an occult HBV infection in these individuals, the liver related mortality might be reduced. The prevalence and clinical importance of isolated antiHBc in Thai have not been investigated yet. There is also limited data of HBV vaccine response in this setting.
Condition | Intervention |
---|---|
Hepatitis B Virus |
Biological: HBV vaccine |
Study Type: | Interventional |
Study Design: | Prevention, Non-Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | The Efficacy of HBV Vaccine Response and Prevalence of Occult HBV Infection in Isolated Anti HBc Between HIV Infected and HIV un-Infected Thai Patients |
Estimated Enrollment: | 200 |
Study Start Date: | December 2006 |
Estimated Study Completion Date: | June 2008 |
Estimated Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
HBV vaccine
|
Biological: HBV vaccine
HBV vaccine 3 doses at month 0, 1, and 6
|
The prevalence of the Hepatitis B core antigen (anti-HBc)in the Thai population is about 70 %. No data of isolated anti-HBc is reported. Anti-HBc antigen is observed in 10%-20% of individuals from low endemic areas of HBV infection. The prevalence of isolated antiHBc antigen is expected to be higher in endemic areas of HBV infection. There is conflicting data of occult HBV infection in HIV-infected patients. In Thailand, perinatal transmission is the main route of HBV transmission, different from developed countries. Therefore, isolated anti-HBc in Thai people has longer duration than low prevalence regions. Moreover, HBV genotype C and B is common in this region. HBV genotype C is correlated with more cirrhosis and hepatoma than genotype B. A study from Taiwan demonstrated that HBV DNA > 100,000 copies/ml is correlated with cirrhosis and hepatoma. Sustained reduction of HBV replication lowers the risk of hepatoma in HBV related cirrhosis. If the HBV vaccination could eliminate an occult HBV infection in these individuals, the liver related mortality will be reduced.
The prevalence and its clinical importance of isolated anti-HBc in the Thai population has not been investigated yet. There is also limited data of HBV vaccine response in this setting.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Thailand | |
HIV-NAT Thai Red Cross AIDS Research Center | |
Bangkok, Thailand, 10330 |
Principal Investigator: | Anchalee Avihingsanon, MD | HIV-NAT, Thai Red Cross AIDS Research Center |
Responsible Party: | HIV-NAT ( Kiat Ruxrungtham ) |
Study ID Numbers: | HIV-NAT 036 |
Study First Received: | May 20, 2007 |
Last Updated: | March 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00476411 |
Health Authority: | Thailand: Food and Drug Administration |
isolated HBc HBV vaccine response occult HBV in isolated antiHBC compared HIV to non HIV |
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases HIV Infections |
Acquired Immunodeficiency Syndrome Hepatitis B Hepatitis, Viral, Human DNA Virus Infections |
Hepadnaviridae Infections |